Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Recruiting 6Not yet recruiting 3Completed 3Active not recruiting 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Vomiting 1Neoplasms 1Nausea 1Muscular Atrophy 1Child Nutrition Disorders 1Breast Neoplasms 1

Interventions

pembrolizumab 244Nivolumab 140Cisplatin 135Cyclophosphamide 134Paclitaxel 113Carboplatin 108Gemcitabine 98Radiotherapy 83Dexamethasone 83Docetaxel 77atezolizumab 68Ipilimumab 68Doxorubicin 62Fluorouracil 60Blood Specimen Collection 58Bevacizumab 58fludarabine 54Rituximab 54Etoposide 53Oxaliplatin 52Surveys and Questionnaires 49Lenalidomide 49Prednisone 47Standard of Care 45Magnetic Resonance Spectroscopy 45Cetuximab 44Capecitabine 44lenvatinib 43Radiosurgery 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Olanzapine × 1 year × Clear all
NCT07403370 2026-05-19

Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis

Shandong Cancer Hospital and Institute

Completed
2,000 enrolled

Nausea, Vomiting

NCT03367572 2025-09-25

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

University of Rochester

Phase 3 Completed
1,363 enrolled 20 charts
Breast

Breast Neoplasms

NCT06175273 2025-09-18

POINT

University of Kentucky

Phase 2/3 Completed
19 enrolled

Muscular Atrophy, Neoplasms, Child Nutrition Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡